We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

22 hedge funds and large institutions have $4.26M invested in Moleculin Biotech in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

17% less capital invested

Capital invested by funds: $5.16M → $4.26M (-$900K)

19% less funds holding

Funds holding: 27 → 22 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
22
Holders Change
-5
Holders Change %
-18.52%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
3
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$157K
2
Renaissance Technologies
Renaissance Technologies
New York
+$74.9K
3
BlackRock
BlackRock
New York
+$32.8K
4
Citadel Advisors
Citadel Advisors
Florida
+$21.1K
5
TSS
Two Sigma Securities
New York
+$14K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$122K
2
WIC
Whitegate Investment Counselors
New Hampshire
-$51.5K
3
Jane Street
Jane Street
New York
-$42K
4
ARTA
A.R.T. Advisors
New York
-$31K
5
HF
HRT Financial
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.38M -$2.34K -1 -0.1%
Renaissance Technologies
2
Renaissance Technologies
New York
$922K +$74.9K +32 +8%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$137K +$157K +67 New
Truist Financial
4
Truist Financial
North Carolina
$128K – – –
BlackRock
5
BlackRock
New York
$127K +$32.8K +14 +30%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$115K – – –
WIC
7
Whitegate Investment Counselors
New Hampshire
$93K -$51.5K -22 -33%
Millennium Management
8
Millennium Management
New York
$88K -$122K -52 -55%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$65K – – –
Northern Trust
10
Northern Trust
Illinois
$61K – – –
Morgan Stanley
11
Morgan Stanley
New York
$32K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$19K +$21.1K +9 New
RJFSA
13
Raymond James Financial Services Advisors
Florida
$18K – – –
UBS Group
14
UBS Group
Switzerland
$18K +$9.37K +4 +80%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$16K – – –
TSS
16
Two Sigma Securities
New York
$13K +$14K +6 New
Commonwealth Equity Services
17
Commonwealth Equity Services
Massachusetts
$10K – – –
Wells Fargo
18
Wells Fargo
California
$3K – – –
CTB
19
Country Trust Bank
Illinois
$2K – – –
PFGIA
20
Patriot Financial Group Insurance Agency
Massachusetts
$2K – – –
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$2K – – –
APA
22
American Portfolios Advisors
New York
$1.83K – – –
Carson Wealth (CWM LLC)
23
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$1K – – –
GRP
25
Global Retirement Partners
California
$1K – – –
1
2

MBRX Hedge Fund Activity: Q4 2019 in Review

22 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2019, worth a combined $4.26M — down 17% from $5.16M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of MBRX and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $157K. The largest seller was Millennium Management, cutting an estimated $122K.

  • 22 institutional investors held Moleculin Biotech (MBRX) as of Q4 2019, down from 27 in Q3 2019.
  • Funds reported $4.26M of Moleculin Biotech stock for Q4 2019, down 17% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q4 2019 and 8 closed out, a net change of -5 holders.
  • The largest Moleculin Biotech buyer in Q4 2019 was Susquehanna International Group, an estimated $157K added.
  • The largest Moleculin Biotech seller in Q4 2019 was Millennium Management, an estimated $122K sold.

Based on aggregated 13F filings for Q4 2019.